PRIMARY STUDY
Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease
Key Findings: Urinary levels of liver-type fatty acid binding protein (L-FABP) appear to accurately correlate with the severity of kidney disease in patients with diabetic kidney failure.
Type of Study: Meta-analysis
Study Sample Size: 180
Study Result: Negative
Research Location(s): China
Year of Pub: 2016
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Ligands Studied: Insulin
Route of Administration: Endogenous
Citation: Yang X, et al. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease. BMC Complement Altern Med. 2016; 16:246. doi: 10.1186/s12906-016-1228-4
Authors: Yang X, Zhang B, Lu X, Yan M, Wen Y, Zhao T, Li P
